{
    "id": 8192,
    "fullName": "STK11 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "STK11 inact mut indicates that this variant results in a loss of function of the Stk11 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 6794,
        "geneSymbol": "STK11",
        "terms": [
            "STK11",
            "hLKB1",
            "LKB1",
            "PJS"
        ]
    },
    "variant": "inact mut",
    "createDate": "06/25/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 887,
                "therapyName": "RDEA119",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9794,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9801,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5447,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5060,
                    "pubMedId": 20142330,
                    "title": "Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20142330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489).",
            "molecularProfile": {
                "id": 8084,
                "profileName": "STK11 inact mut"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7607,
                    "pubMedId": 27821489,
                    "title": "A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5408,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 3861,
                "therapyName": "Phenformin + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5053,
                    "pubMedId": 26574479,
                    "title": "Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26574479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to Adavosertib (MK-1775) compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10705,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775)5 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 4186,
                "therapyName": "Adavosertib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5409,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",
            "molecularProfile": {
                "id": 20862,
                "profileName": "KRAS G12D STK11 inact mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5053,
                    "pubMedId": 26574479,
                    "title": "Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26574479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6336,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).",
            "molecularProfile": {
                "id": 23102,
                "profileName": "KRAS G12S STK11 inact mut"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8084,
            "profileName": "STK11 inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 8388,
                    "name": "mTOR Inhibitor",
                    "profileName": "STK11 inact mut"
                },
                {
                    "id": 7106,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "STK11 inact mut"
                }
            ]
        },
        {
            "id": 20861,
            "profileName": "KRAS mut STK11 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20862,
            "profileName": "KRAS G12D STK11 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23102,
            "profileName": "KRAS G12S STK11 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}